USPTO Examiner WEBB WALTER E - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18951096Lip Balm Containing Caffeine, Nicotine or TestosteroneNovember 2024March 2025Allow410NoNo
18842405ORAL CARE PRODUCTAugust 2024February 2025Allow500NoNo
18781282LIP BALM CONTAINING CAFFEINE, NICOTINE OR TESTOSTERONEJuly 2024August 2024Allow100NoNo
18781300LIP BALM CONTAINING CAFFEINE, NICOTINE OR TESTOSTERONEJuly 2024August 2024Allow100NoNo
18614050Core Shell Silica Particles and Use for Malodor ReductionMarch 2024March 2025Allow1210NoNo
18602863ORAL HYGIENE COMPOSITIONS AND METHODS OF USEMarch 2024March 2025Allow1210NoNo
18586163ORAL HYGIENE COMPOSITIONS AND METHODS OF USEFebruary 2024August 2024Allow510YesNo
18404339ORAL CARE ARTICLE COMPRISING A HYDROPHOBIC DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING A BLEACHING AGENTJanuary 2024December 2024Allow1110NoNo
18525147WATER SOLUBLE COMPOSITION AND PRODUCTION METHOD THEREOFNovember 2023January 2024Allow200NoNo
18495126ORAL CARE ARTICLE COMPRISING A HYDROPHOBIC DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING AN ACTIVE AGENTOctober 2023August 2024Allow1010NoNo
18495174ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING A BLEACHING AGENTOctober 2023August 2024Allow1010NoNo
18495090ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING A BLEACHING AGENTOctober 2023August 2024Allow1010NoNo
18217568WOUND CLEANSING METHODJuly 2023June 2024Allow1210YesNo
18214964COMPOSITIONS AND METHODS FOR DENTAL MINERALIZATIONJune 2023June 2024Allow1210NoNo
18133529WHITENING TOOTHPASTE CAPABLE OF EFFECTIVELY REMOVING DENTAL PLAQUE AND TARTARApril 2023July 2023Allow300NoNo
18029864TOPICAL COMPOSITION FOR NANOBUBBLE COSMETICMarch 2023August 2024Allow1621NoNo
18191219OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCERMarch 2023January 2024Abandon1010NoNo
18169367Core Shell Silica Particles and Use for Malodor ReductionFebruary 2023November 2023Allow910NoNo
18161529Dentifrice composition comprising non-crustacean derived chitosanJanuary 2023February 2025Abandon2520NoYes
18159019DENTAL MATERIAL COMPOSITIONS FOR CLEANSING AND REMOVAL OF ANIONIC CONTAMINANTS FROM SUBSTRATES & THEIR METHODS OF USEJanuary 2023June 2025Allow2900NoNo
18101047Nasal Hygiene Method and FormulationJanuary 2023March 2025Abandon2630YesNo
18098033METHOD FOR PROVIDING A BEVERAGE ADDITIVEJanuary 2023April 2025Allow2700NoNo
18084879Toothpaste CompositionDecember 2022May 2025Abandon2840YesNo
18082737COMPOSITIONS AND METHODS FOR TREATING CENTRALLY MEDIATED NAUSEA AND VOMITINGDecember 2022March 2024Allow1520NoNo
18066730SOLUBLE FIBER LOZENGEDecember 2022June 2024Allow1830NoNo
18046312MULTIVESICULAR LIPOSOME FORMULATIONS OF DEXAMETHASONEOctober 2022December 2024Allow2730NoYes
18046416BUPIVACAINE MULTIVESICULAR LIPOSOME FORMULATIONS AND USES THEREOFOctober 2022December 2024Allow2730NoYes
17962748Thermally Gelling Drug FormulationsOctober 2022August 2023Abandon1021NoNo
17915453PROCESS FOR PRODUCTION OF VITAMIN ASeptember 2022May 2025Allow3100NoNo
17888242COMPOSITIONS, PRODUCTS, SYSTEM, AND METHOD FOR PERMING HAIRAugust 2022January 2024Allow1711NoNo
17887237Oral Care CompositionsAugust 2022August 2023Abandon1220NoNo
17869261Method for Producing Pet Dental TreatJuly 2022May 2024Allow2200NoNo
17811035ORAL CARE COMPOSITIONSJuly 2022December 2023Allow1720NoNo
17853862Zinc - Amino Acid - Lauryl Sulfate Complex with Antimicrobial ActivityJune 2022October 2023Allow1611NoNo
17853788Oral Care CompositionsJune 2022June 2023Allow1110NoNo
17847852NANO-EMULSION COMPOSITION FOR TOOTH WHITENING AND METHOD FOR PRODUCING THE SAMEJune 2022September 2024Allow2740NoNo
17807399ANTISEPTIC AND/OR ANTI-INFLAMMATORY GEL FOR TREATMENT OF ORAL CAVITY DISEASES COMPRISING POLYVINYL ALCOHOL AND POLYACIDSJune 2022August 2024Abandon2630NoNo
17785203ASSEMBLY AND METHOD FOR THE PREPARATION OF A WOUND DRESSINGJune 2022May 2025Allow3601NoNo
17757161A MATERIAL FOR THE MANUFACTURING OF OPHTHALMIC IMPLANTS BY PHOTO-POLYMERIZATION METHODJune 2022February 2025Allow3200NoNo
17832556COMPOSITIONS AND METHODS FOR DENTAL MINERALIZATIONJune 2022March 2023Allow1010NoNo
17831150Orally Adhering Lozenges Containing Soluble Dietary FiberJune 2022October 2024Allow2940NoYes
17828179Oral Care Composition Comprising RottlerinMay 2022May 2024Abandon2320NoYes
17746817ORAL HYGIENE COMPOSITIONS AND METHODS OF USEMay 2022January 2024Allow2021NoNo
17661153LIPOSOME COMPRISING RAPAMYCIN OR A DERIVATIVE THEREOF AND USE THEREOF IN THERAPYApril 2022June 2025Allow3740YesNo
17717391Process For Making An Oral Care Article Of ManufactureApril 2022December 2023Allow2120NoNo
17656307Oral Care CompositionsMarch 2022November 2023Abandon1911NoNo
17694044Oral Care Compositions and Methods of Using the CompositionsMarch 2022June 2025Abandon3920NoYes
17642565SYSTEM FOR CORNEAL CROSS-LINKING AND CORRECTING VISION BY USING LED CONTACT LENS AND EYE DYEMarch 2022May 2025Allow3800NoNo
17652948Oral Care Whitening CompositionsMarch 2022February 2023Allow1210NoNo
17652496Antiperspirant that Reduces/Eliminates Yellowing on ClothingFebruary 2022October 2024Abandon3141YesNo
17675285Peroxymonosulfate Whitening StripsFebruary 2022September 2024Allow3140NoNo
17668840Dental Medicament ApplicatorFebruary 2022May 2022Allow300NoNo
17568709DITHIONITE SHELF-STABLE SWEETENERSJanuary 2022February 2024Abandon2520NoNo
17620089PRODUCT FOR DYEING KERATINOUS MATERIAL, CONTAINING AMINOSILICONE, A CHROMOPHORIC COMPOUND, PRESERVATIVE AND ETHOXYLATED FATTY ALCOHOLDecember 2021June 2025Abandon4220NoNo
17618664WATER-IN-OIL EMULSION COMPOSITIONDecember 2021June 2024Allow3000NoNo
17542370MANUFACTURE OF FREEZE-DRIED COSMETICDecember 2021September 2023Abandon2220NoNo
17539273ELECTROSPUN DEXTRAN FIBERS AND DEVICES FORMED THEREFROMDecember 2021August 2024Allow3321NoNo
17538201STABLE COMPOSITIONS OF UNCOMPLEXED IODINE AND METHODS OF USENovember 2021January 2023Allow1410NoNo
17529319Making An Oral Care Article Of ManufactureNovember 2021April 2023Abandon1710NoNo
17611862PHARMACEUTICAL COMPOSITION FOR JOINT DISEASE TREATMENT AND METHOD FOR PRODUCING SAMENovember 2021May 2025Abandon4201NoNo
17610356IMMUNE-STIMULATING COMPOSITIONS FOR AQUACULTURE SPECIESNovember 2021April 2025Abandon4101NoNo
17519931Oral Care Whitening CompositionsNovember 2021January 2022Allow300NoNo
17519068MODIFIER SYSTEM FOR COMPOSITIONS CONTAINING LAYERED DOUBLE HYDROXIDENovember 2021April 2023Allow1710NoNo
17512153OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCEROctober 2021March 2023Abandon1710NoNo
17606637DUCTILE COATING FOR AN IMPLANT COMPONENTOctober 2021June 2024Allow3100NoNo
16770787INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST A BASAL INSULIN WHICH PI IS COMPRISED BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID BEARING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALSOctober 2021January 2025Abandon5610NoNo
17599725LONG-LASTING COSMETIC COMPOSITIONSeptember 2021September 2024Allow3510NoNo
17599081FUSION PROTEIN COMPRISING GROWTH DIFFERENTIATION FACTOR 11 AND HEAT SHOCK PROTEIN 10 WITH ENHANCED SKIN CELL PROLIFERATION EFFECT AND COSMETIC COMPOSITION FOR ANTI-WRINKLE COMPRISING THE SAME AS EFFECTIVE COMPONENTSeptember 2021September 2024Allow3600NoNo
17598647PREPARATIONS CONTAINING BERRY EXTRACTS FOR USE IN THE PROPHYLAXIS AND/OR TREATMENT OF VIRAL INFECTIONS CAUSED BY HERPESVIRIDAESeptember 2021May 2025Abandon4411NoNo
17598455ANTIPERSPIRANT AND DEODORANT COMPOSITIONSSeptember 2021April 2022Allow700NoNo
17442818POLYMER DRUGSeptember 2021August 2024Allow3410NoNo
17593730TOPICAL COMPOSITION FOR TREATING BAD BODY ODORS, IN PARTICULAR HALITOSISSeptember 2021April 2024Allow3120NoNo
17481509ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING AN ACTIVE AGENTSeptember 2021July 2023Allow2210NoNo
17481377Oral Care Article Comprising a Hydrophobic Delivery Carrier and Solid Hydrophilic Particle Comprising a Bleaching AgentSeptember 2021July 2023Allow2210NoNo
17481524ORAL CARE ARTICLE COMPRISING A DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING A BLEACHING AGENTSeptember 2021July 2023Allow2210NoNo
17481498Oral Care Article Comprising A Hydrophobic Delivery Carrier And Solid Hydrophilic Particles Comprising A Bleaching AgentSeptember 2021November 2023Allow2620NoNo
17481397ORAL CARE ARTICLE COMPRISING A HYDROPHOBIC DELIVERY CARRIER AND SOLID HYDROPHILIC PARTICLES COMPRISING AN ACTIVE AGENTSeptember 2021July 2023Allow2210NoNo
17440167DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOFSeptember 2021December 2024Abandon3901NoNo
17468571ORAL COMPOSITIONSSeptember 2021March 2023Allow1810NoNo
17468549ORAL COMPOSITIONSSeptember 2021March 2023Allow1810NoNo
17468518ORAL COMPOSITIONSSeptember 2021January 2023Allow1710NoNo
17436557PROCESS FOR THE PREPARATION AND USE OF HAIR TREATMENT COMPOSITIONS CONTAINING ORGANIC C1-C6 ALKOXY SILANESSeptember 2021January 2025Abandon4010NoNo
17435501Biodegradable Two-Layered Matrix for Preventing Post-Surgical AdhesionsSeptember 2021April 2024Allow3200NoNo
17464122NASAL HYGIENE METHOD AND COMPOSITIONSeptember 2021October 2023Abandon2520NoNo
17431529AN ORAL REMINERALIZATION ACCELERATING COMPOSITIONAugust 2021October 2024Abandon3830NoNo
17388562Novel Processes and MethodsJuly 2021February 2023Allow1900NoNo
17383540Oral Care Composition for Long-Lasting Peroxide DeliveryJuly 2021April 2024Abandon3340NoNo
17372604ORGANIC TOOTHPASTEJuly 2021December 2021Allow510NoNo
17363055MINERALIZATION AGENT AND MOUTH WASH COMPRISING THE SAMEJune 2021May 2023Allow2200NoNo
17360968HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONSJune 2021April 2024Allow3320NoNo
17304901ADHESIVE PATCH TO ORAL CAVITY HAVING IMPROVED STABILITY AND USABILITYJune 2021September 2022Allow1400NoNo
17356000Zinc Phosphate Containing CompositionsJune 2021August 2023Abandon2620NoNo
17415359COMPOSITIONS AND METHODS FOR REMOVING DENTAL CALCULIJune 2021January 2024Abandon3111YesNo
17414270ANTIMICROBIAL COMPOSITIONS COMPRISING MODIFIED CLAY AND NONIONIC TRIBLOCK COPOLYMERSJune 2021May 2023Allow2300NoNo
17312985FIBER FOR ARTIFICIAL HAIR AND HEAD ACCESSORY PRODUCTJune 2021October 2023Allow2910NoNo
17312974SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR CHRONOTROPIC ADMINISTRATION OF DIPEPTIDYL PEPTIDASE IV INHIBITORSJune 2021February 2025Abandon4420NoNo
17344572EFFECTIVE TEETH WHITENING COMPOSITION UTILIZING BROMELAIN ENZYMESJune 2021May 2024Abandon3621NoYes
17298777A SULFONATED POLYSTYRENE DERIVATIVE FOR USE IN THE TREATMENT AND/OR PROPHYLAXIS OF CAT FLUJune 2021August 2023Allow2600NoNo
17303059Oral Care Composition for Long-Lasting Peroxide DeliveryMay 2021April 2024Abandon3540NoNo
17292386TRIS-SUBSTITUTED BIGUANIDE COMPOUNDS AND THEIR USESMay 2021March 2024Allow3400NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner WEBB, WALTER E.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
94
Examiner Affirmed
80
(85.1%)
Examiner Reversed
14
(14.9%)
Reversal Percentile
25.3%
Lower than average

What This Means

With a 14.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
209
Allowed After Appeal Filing
41
(19.6%)
Not Allowed After Appeal Filing
168
(80.4%)
Filing Benefit Percentile
21.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 19.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner WEBB, WALTER E - Prosecution Strategy Guide

Executive Summary

Examiner WEBB, WALTER E works in Art Unit 1612 and has examined 1,029 patent applications in our dataset. With an allowance rate of 52.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.

Allowance Patterns

Examiner WEBB, WALTER E's allowance rate of 52.1% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by WEBB, WALTER E receive 2.32 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by WEBB, WALTER E is 30 months. This places the examiner in the 39% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +11.0% benefit to allowance rate for applications examined by WEBB, WALTER E. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.2% of applications are subsequently allowed. This success rate is in the 8% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 20.7% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 30.5% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 44.0% of appeals filed. This is in the 7% percentile among all examiners. Of these withdrawals, 44.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 66.3% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.1% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.